Literature DB >> 15118874

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.

Yoshikazu Okamoto1, Pier-Luigi Di Patre, Christoph Burkhard, Sonja Horstmann, Benjamin Jourde, Michael Fahey, Danielle Schüler, Nicole M Probst-Hensch, M Gazi Yasargil, Yasuhiro Yonekawa, Urs M Lütolf, Paul Kleihues, Hiroko Ohgaki.   

Abstract

We carried out a population-based study on low-grade diffuse gliomas in the Canton of Zurich, Switzerland (population 1.16 million). From 1980 to 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 122 (12.4%) were low-grade (WHO grade II). The incidence rates adjusted to the World Standard Population, per million population per year, were 2.28 for low-grade diffuse astrocytomas, 0.89 for oligoastrocytomas, and 2.45 for oligodendrogliomas. The survival rate (mean follow-up 7.5+/-4.8 years) was highest for patients with oligodendroglioma (78% at 5 years, 51% at 10 years), followed by those with oligoastrocytoma (70% at 5 years, 49% at 10 years) and fibrillary astrocytoma (65% at 5 years, 31% at 10 years). Survival of patients with gemistocytic astrocytoma was poor, with survival rates of 16% at 5 years and 0% at 10 years. Younger patients (<50 years) survived significantly longer than older patients (>50 years; P=0.013). DNA sequencing, performed in 84% of cases, revealed that TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but were infrequent (13%) in oligodendrogliomas. The presence of TP53 mutations was associated with shorter survival of patients with low-grade diffuse gliomas (log-rank test; P=0.047), but when each histological type was analyzed separately, an association was observed only for oligoastrocytoma ( P=0.05). Loss on 1p and 19q were assessed by quantitative microsatellite analysis in 67% of cases. These alterations were frequent in oligodendrogliomas (1p, 57%; 19q, 69%), less common in oligoastrocytomas (1p, 27%; 19q, 45%), rare in fibrillary astrocytomas (1p, 7%; 19q, 7%), and absent in gemistocytic astrocytomas. None of these alterations were predictive of survival. These results establish the frequency of key genetic alterations in low-grade diffuse gliomas at a population-based level. Multivariate Cox's regression analysis indicates that only age and histological type, but not genetic alterations, are significant predictive factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118874     DOI: 10.1007/s00401-004-0861-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  95 in total

1.  Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Yoshinori Higuchi; Naokatsu Saeki
Journal:  J Neurooncol       Date:  2010-08-19       Impact factor: 4.130

2.  High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma.

Authors:  Kiyotaka Saito; Kiyotaka Yokogami; Kazunari Maekawa; Yuichiro Sato; Shinji Yamashita; Fumitaka Matsumoto; Asako Mizuguchi; Hideo Takeshima
Journal:  Hum Cell       Date:  2021-01-17       Impact factor: 4.174

3.  Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France.

Authors:  Amélie Darlix; Sonia Zouaoui; Jean-Marc Virion; Valérie Rigau; Hélène Mathieu-Daudé; Marie Blonski; German Reyes-Botero; Faiza Bessaoud; Brigitte Trétarre; Fabienne Bauchet; Laurent Capelle; Michel Fabbro; Christine Kerr; Dominique Figarella-Branger; Hugues Duffau; Luc Taillandier; Luc Bauchet
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

4.  Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Authors:  Manila Antonelli; Francesca Romana Buttarelli; Antonietta Arcella; Sumihito Nobusawa; Vittoria Donofrio; Hiroko Oghaki; Felice Giangaspero
Journal:  J Neurooncol       Date:  2010-02-21       Impact factor: 4.130

5.  Long-term survival in children under 3 years of age with low-grade astrocytoma.

Authors:  Roberto Rivera-Luna; Marta Zapata-Tarrés; Aurora Medina-Sansón; Enrique López-Aguilar; Ana Niembro-Zúñiga; J Amador Zarco; Alfonso Marhx-Bracho; Fernando Rueda-Franco; Leticia Bornstein-Quevedo
Journal:  Childs Nerv Syst       Date:  2007-01-17       Impact factor: 1.475

Review 6.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

7.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

8.  Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.

Authors:  Nathalie L Jansen; Christoph Schwartz; Vera Graute; Sabina Eigenbrod; Jürgen Lutz; Rupert Egensperger; Gabriele Pöpperl; Hans A Kretzschmar; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich-Wilhelm Kreth; Christian la Fougère; Niklas Thon
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 9.  Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity.

Authors:  Evan Noch; Kamel Khalili
Journal:  Cancer Biol Ther       Date:  2009-10       Impact factor: 4.742

10.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Authors:  Fabio M Iwamoto; Linda Nicolardi; Alexis Demopoulos; Violetta Barbashina; Paulo Salazar; Marc Rosenblum; Adília Hormigo
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.